Engineered anti-IL-23 antibodies
View Patent ↗Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
1. A purified antibody, or antigen binding fragment thereof, that binds to human IL-23 (SEQ ID NO: 29), said antibody or antigen binding fragment comprising:
a) a CDR-L1 sequence consisting of residues 43-53 of SEQ ID NO: 2;
b) a CDR-L2 sequence consisting of residues 69-75 of SEQ ID NO: 2;
c) a CDR-L3 sequence consisting of residues 108-116 of SEQ ID NO: 2;
d) a CDR-H1 sequence consisting of residues 45-54 of SEQ ID NO: 1;
e) a CDR-H2 sequence consisting of residues 69-85 of SEQ ID NO: 1; and
f) a CDR-H3 sequence consisting of residues 118-123 of SEQ ID NO: 1.
2. The purified antibody or antigen binding fragment of claim 1 comprising:
a) a light chain variable domain sequence consisting of residues 20-129 of SEQ ID NO: 2; and
b) a heavy chain variable domain sequence consisting of residues 20-134 of SEQ ID NO: 1.
3. The purified antibody or antigen binding fragment of claim 2 comprising:
a) a light chain consisting of residues 20-233 of SEQ ID NO: 2; and
b) a heavy chain consisting of residues 20-464 of SEQ ID NO: 1.
4. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of the antibody or antigen binding fragment of claim 1 to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay.
5. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of the antibody or antigen binding fragment of claim 2 to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay.
6. A monoclonal antibody or antigen binding fragment of claim 4 .
7. A monoclonal antibody or antigen binding fragment of claim 5 .
8. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of a second antibody to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay, wherein the second antibody comprises:
a) a light chain consisting of residues 20-233 of SEQ ID NO: 2; and
b) a heavy chain consisting of residues 20-464 of SEQ ID NO: 1.
9. A monoclonal antibody or antigen binding fragment of claim 6 .
10. A purified antibody, or antigen binding fragment thereof, that binds to human IL-23 (SEQ ID NO: 29), said antibody or antigen binding fragment comprising:
a) a CDR-L1 sequence consisting of residues 43-53 of SEQ ID NO: 4;
b) a CDR-L2 sequence consisting of residues 69-75 of SEQ ID NO: 4;
c) a CDR-L3 sequence consisting of residues 108-116 of SEQ ID NO: 4;
d) a CDR-H1 sequence consisting of residues 45-54 of SEQ ID NO: 3;
e) a CDR-H2 sequence consisting of residues 69-85 of SEQ ID NO: 3; and
f) a CDR-H3 sequence consisting of residues 118-123 of SEQ ID NO: 3.
11. The purified antibody or antigen binding fragment of claim 10 comprising:
a) a light chain variable domain sequence consisting of residues 20-129 of SEQ ID NO: 4; and
b) a heavy chain variable domain sequence consisting of residues 20-134 of SEQ ID NO: 3.
12. The purified antibody or antigen binding fragment of claim 11 comprising:
a) a light chain consisting of residues 20-233 of SEQ ID NO: 4; and
b) a heavy chain consisting of residues 20-464 of SEQ ID NO: 3.
13. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of the antibody or antigen binding fragment of claim 10 to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay.
14. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of the antibody or antigen binding fragment of claim 11 to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay.
15. A monoclonal antibody or antigen binding fragment of claim 13 .
16. A monoclonal antibody or antigen binding fragment of claim 14 .
17. A purified antibody, or antigen binding fragment thereof, that is able to block the binding of a second antibody to human IL-23p19 (SEQ ID NO: 29) in a cross-blocking assay, wherein the second antibody comprises:
a) a light chain consisting of residues 20-233 of SEQ ID NO: 4; and
b) a heavy chain consisting of residues 20-464 of SEQ ID NO: 3.
18. A monoclonal antibody or antigen binding fragment of claim 17 .